
Our objective was to determine whether an immune response can be generated against zzso zzso and against tumor cell zzso after vaccination with zzso zzso zzso zzso zzso plus zzso in breast cancer zzso Nine patients with a history of breast cancer but without evidence of disease were treated with zzso zzso plus zzso containing 100 zzso of zzso and 100 zzso of zzso zzso zzso were administered at weeks 1, 2, 3, 7, and zzso zzso blood was drawn at frequent intervals to assess zzso zzso zzso tests were placed at weeks 1, 3, 9, and 21 to determine delayed type hypersensitivity zzso Common zzso included a local skin reaction at the site of the zzso usually of 4-5 days' zzso and mild zzso symptoms usually of 1-2 days' zzso High zzso and zzso zzso zzso against synthetic zzso were zzso zzso zzso zzso remain elevated from a minimum of zzso weeks after the first zzso zzso of zzso zzso to zzso tumor cells was observed in seven patients, although there was minimal binding of zzso zzso Two patients developed significant zzso zzso zzso chemotherapy and stem cell zzso There was no evidence of T cell zzso This zzso zzso plus zzso was zzso and well tolerated in breast cancer zzso Additional trials are ongoing to determine the optimal zzso zzso for use in larger clinical zzso Further investigation of vaccine therapy in high-risk breast cancer is zzso 

